GENetic Fronto Temporal Dementia Initiative in Lille
ConditionFrontotemporal Dementia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Lille
About this trial
GENFI Lille is a French cohort that belongs to the international initiative GENFI2, a five year longitudinal biomarker cohort study of genetic FTD and its associated disorders (including MND/ALS) investigating members of families with a known mutation in GRN or MAPT or an expansion in C9orf72 (including those affected with the disorder as well as at-risk members of families).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
The participant must be 18 years old or older.
An affected member is one who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the FTD spectrum.
An at-risk member is one who is a first-degree relative of a family member affected with the disease.
Pathogenicity of a GRN or MAPT mutation is defined by those included within the GENFI list of FTD mutation. If a novel mutation is discovered that is likely to be pathogenic and has not yet been included within the FTD mutation database then the GENFI Genetics Core will decide on inclusion. Please send an email to the GENFI Trials Team at [email protected].
Disqualifiers
Participant has another medical or psychiatric illness that would interfere in completing assessments.
Contraindications to FDG-PET (allergy to FDG…)
Participant is pregnant.
Trial design
Design model
Parallel
Treatments tested in this trial
Investigation procedures
Diagnostic testAll participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
Treatment groups
20 Participants
are divided into 2 treatment groupsGroup A: asymptomatic at-risk individualOther 1 intervention
Group B: symptomatic individualOther 1 intervention
Trial outcomes
Primary outcomes
1
Difference of the proportion of symptomatic FTD patients or presymptomatic subjects at risk of genetic FTD
Characterization of patients and describe multi characteristics of disease
Time frame
each year during 2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov